| Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. | |
| | |
MedLine Citation:
|
PMID: 15447754 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) has been incriminated to play an important role in the pathogenesis of nonalcoholic steatohepatitis (NASH). Pentoxifylline, a TNF-alpha inhibitor could prove useful in treating patients with NASH. METHODS: Eighteen patients (mean age, 34 +/- 7.8 yr) with histologically proven NASH and with persistently elevated ALT (>1.5 times) were given pentoxifylline at a dosage of 400 mg t.i.d. for 6 months. No lipid-lowering agent or antioxidants were concurrently advised. RESULTS: Impaired fasting glycemia, impaired glucose tolerance, diabetes mellitus, and hypertriglyceridemia were noted in 6, 35, 17, and 53% of the patients, respectively. After 6 months of therapy, fatigue improved (55.6 vs 20%, p= 0.016), but serum triglyceride (182 +/- 66 vs 160 +/- 55 mg/dl, p= 0.397), cholesterol (173 +/- 46 vs 162 +/- 40 mg/dl, p= 0.440), and body mass index (BMI) (27.3 +/- 3.1 vs 26 +/- 3.1 kg/m(2), p= 0.087) remained unchanged. Mean AST (66 +/- 29 vs 33 +/- 11 IU/l, p < 0.0001) and ALT (109 +/- 44 vs 47 +/- 20 IU/l, p < 0.0001) reduced significantly. ALT normalized in 23% at month 1 (p= 0.125), 35% at month 2 (p= 0.125), and 60% at month 6 (p= 0.008) of treatment. The insulin resistance index assessed by homeostatic metabolic assessment (HOMA(IR)) improved (5.1 +/- 3.4 vs 2.6 +/- 2, p = 0.046) and the serum TNF-alpha reduced significantly after therapy (22.15 +/- 2.49 vs 17 +/- 2.58 pg/ml, p = 0.011). The drug was well tolerated. CONCLUSIONS: In patients with NASH, pentoxifylline therapy effectively achieved significant clinical and biochemical improvement with reduction in HOMA(IR). These benefits are possibly mediated through suppression of TNF-alpha. |
| | |
Authors:
|
Sanjay K Satapathy; Sanjay Garg; Ranjeet Chauhan; Puja Sakhuja; Veena Malhotra; Barjesh C Sharma; Shiv K Sarin |
Related Documents
:
|
16919544 - Serum levels of interleukin 6, c-reactive protein, vascular cell adhesion molecule 1, a... 16499154 - Acanthosis nigricans, insulin resistance (homa) and dyslipidemia among native american ... 20126854 - Relationship between insulin and hypogonadism in men with metabolic syndrome. 17264514 - Effect of estrogen therapy on insulin resistance and plasminogen activator inhibitor ty... 15182964 - Multi-generation cadmium acclimation and tolerance in daphnia magna straus. 18261204 - Suspected retinopathies in norwegian optometric practice with emphasis on patients with... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The American journal of gastroenterology Volume: 99 ISSN: 0002-9270 ISO Abbreviation: Am. J. Gastroenterol. Publication Date: 2004 Oct |
Date Detail:
|
Created Date: 2004-09-27 Completed Date: 2004-12-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0421030 Medline TA: Am J Gastroenterol Country: United States |
Other Details:
|
Languages: eng Pagination: 1946-52 Citation Subset: IM |
Affiliation:
|
Departments of Gastroenterology and Pathology, GB Pant Hospital, New Delhi 110-002, India. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Fatty Liver / complications, diagnosis, drug therapy*, metabolism* Humans Male Middle Aged Pentoxifylline / therapeutic use* Pilot Projects Tumor Necrosis Factor-alpha / antagonists & inhibitors* |
| Chemical | |
Reg. No./Substance:
|
0/Tumor Necrosis Factor-alpha; 6493-05-6/Pentoxifylline |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Evaluation of polyp detection in relation to procedure time of screening or surveillance colonoscopy...
Next Document: Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate ...